Dynavax Technologies Corporation

NasdaqGS:DVAX 株式レポート

時価総額：US$1.8b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Dynavax Technologies 将来の成長

Future 基準チェック /46

Dynavax Technologiesは、42.6%と12.4%でそれぞれ年率42.6%で利益と収益が成長すると予測される一方、EPSはgrowで46.1%年率。

主要情報

42.6%

収益成長率

46.13%

EPS成長率

Biotechs 収益成長25.4%
収益成長率12.4%
将来の株主資本利益率n/a
アナリストカバレッジ

Low

最終更新日24 Dec 2025

今後の成長に関する最新情報

分析記事 • Nov 08

Dynavax Technologies Corporation Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year

It's been a good week for Dynavax Technologies Corporation ( NASDAQ:DVAX ) shareholders, because the company has just...
分析記事 • May 08

Dynavax Technologies Corporation Reported A Surprise Loss, And Analysts Have Updated Their Forecasts

There's been a notable change in appetite for Dynavax Technologies Corporation ( NASDAQ:DVAX ) shares in the week since...

Recent updates

ナラティブ更新 • Feb 05

DVAX: Cash Acquisition By Sanofi Will Likely Unlock Further Upside

Analysts kept their fair value estimate for Dynavax Technologies steady at US$25.00. They refined inputs such as a slightly higher discount rate, modestly adjusted revenue growth and profit margin assumptions, and a small change in the future P/E they use in their models to better reflect their updated view of the company.
ナラティブ更新 • Jan 22

DVAX: Planned Takeover Will Likely Unlock Upside From Cash Deal

Analysts have maintained their fair value estimate for Dynavax Technologies at US$25.00, with only minor adjustments to assumptions such as discount rate, revenue growth, profit margin, and future P/E to reflect updated views on the company’s risk profile and earnings potential. What's in the News Sanofi agreed to acquire Dynavax Technologies for US$1.9b in cash, valuing shares at US$15.50 each.
ナラティブ更新 • Jan 07

DVAX: Planned Sanofi Acquisition Will Likely Unlock Upside From Conservative Outlook

Analysts have revised their price target on Dynavax Technologies from $32.00 to $25.00, citing updated assumptions for the discount rate, revenue growth, profit margin, and future P/E that indicate a more conservative fair value outlook. What's in the News Sanofi agreed to acquire Dynavax Technologies for a total consideration of US$1.9b, with Dynavax shareholders to receive US$15.50 in cash per share upon completion of the transaction.
分析記事 • Jan 06

Dynavax Technologies Corporation (NASDAQ:DVAX) Surges 42% Yet Its Low P/S Is No Reason For Excitement

Dynavax Technologies Corporation ( NASDAQ:DVAX ) shares have continued their recent momentum with a 42% gain in the...
ナラティブ更新 • Dec 18

DVAX: Buybacks Will Support Future Upside As Pipeline Progress Strengthens Outlook

Analysts have nudged their price target on Dynavax Technologies higher to approximately $19.25 per share. This reflects slightly adjusted assumptions for discount rates, long term revenue growth, profit margins, and forward valuation multiples, which leave their overall fair value estimate broadly unchanged.
ナラティブ更新 • Dec 04

DVAX: Share Buybacks Will Drive Future Upside Despite Lowered Market Multiple

Analysts have trimmed their price target on Dynavax Technologies from 21.80 dollars to 19.25 dollars, reflecting slightly higher discount rate assumptions and a more conservative view on future valuation multiples, despite largely unchanged long term growth and margin expectations. What's in the News Board of Directors authorized a new share repurchase plan in October 2025, enabling the company to buy back common stock.
ナラティブ更新 • Nov 20

DVAX: Share Repurchase And Positive Trial Data Will Drive Further Upside

Analysts have revised their price target for Dynavax Technologies downward from $22.80 to $21.80. They cite slight adjustments to key financial assumptions, including discount rate, revenue growth, and profit margin forecasts.
分析記事 • Nov 08

Dynavax Technologies Corporation Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year

It's been a good week for Dynavax Technologies Corporation ( NASDAQ:DVAX ) shareholders, because the company has just...
Seeking Alpha • Oct 29

Dynavax Technologies Trading At Fair Value

Summary Dynavax's HEPLISAV‑B is its sole revenue generator. HEPLISAV‑B's revenue has grown steadily in a crowded market of hepatitis B vaccines. The market for these vaccines is expected to peak at ~$900 million in 2030 before tailing off afterwards. DVAX expects to grow its percentage share of the hepatitis B market to 60% by 2030. Read the full article on Seeking Alpha
分析記事 • May 08

Dynavax Technologies Corporation Reported A Surprise Loss, And Analysts Have Updated Their Forecasts

There's been a notable change in appetite for Dynavax Technologies Corporation ( NASDAQ:DVAX ) shares in the week since...
分析記事 • Mar 04

We Think Dynavax Technologies' (NASDAQ:DVAX) Profit Is Only A Baseline For What They Can Achieve

The subdued stock price reaction suggests that Dynavax Technologies Corporation's ( NASDAQ:DVAX ) strong earnings...
Seeking Alpha • Mar 03

Dynavax Technologies: A Post-Earnings Assessment With Growing Market Share

Summary Dynavax Technologies posted solid Q4 results and FY 2025 guidance late in February, with Heplisav-B driving revenue growth and profitability. Heplisav-B's market share continues to grow due to its superior efficacy and compliance compared to previous hepatitis B vaccines. Heplisav-B should eventually garner 60% of a market that is predicted to grow to $900 million in the U.S. by 2030. Dynavax Technologies also has large net cash holdings and a promising Shingles vaccine in development. An updated analysis around Dynavax Technologies follows in the paragraphs below. Read the full article on Seeking Alpha
Seeking Alpha • Feb 05

Dynavax Technologies: Time To Refocus On Former Cash Cow CpG1018

Summary HEPLISLAV-B, which is adjuvanted with CpG1018, has key advantages over its principal competition, Engerix-B. The article reviews Dynavax's investment prospects following its Q3 2024 earnings report, preliminary 2024 financial results press release, and latest website presentation. Management's failure to work towards monetizing its CpG1018 adjuvant is unfortunate, in my opinion. Dynavax should take a leaf from its vaccine maker peer, Novavax, and work to monetize its CpG1018 adjuvant. Read the full article on Seeking Alpha
分析記事 • Jan 24

Is Dynavax Technologies (NASDAQ:DVAX) Using Debt In A Risky Way?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Seeking Alpha • Nov 13

Dynavax Technologies: What The Stock Buyback Means, What It Doesn't

Summary Today, we revisit Dynavax Technologies Corporation, whose shares have moved up nicely after the company announced a significant buyback authorization. In addition, DVAX's flagship product, Heplisav-B, continues to increase market share consistently in a growing market. The company has also moved towards profitability, and analyst firms have price targets significantly above the current trading level of the stock, even after its recent rally. An updated analysis around Dynavax Technologies follows in the paragraphs below. Read the full article on Seeking Alpha
分析記事 • Nov 12

Dynavax Technologies Corporation (NASDAQ:DVAX) Surges 31% Yet Its Low P/S Is No Reason For Excitement

Dynavax Technologies Corporation ( NASDAQ:DVAX ) shareholders would be excited to see that the share price has had a...
分析記事 • Oct 12

Is Dynavax Technologies (NASDAQ:DVAX) Using Debt In A Risky Way?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
User avatar
新しいナラティブ • Sep 14

HEPLISAV-B And New Vaccine Trials Set To Skyrocket Revenue And Market Share

Strong HEPLISAV-B sales and market optimism indicate potential for revenue growth and market share expansion in the adult hepatitis B vaccine sector.
Seeking Alpha • Sep 05

Dynavax Technologies: Slow And Steady Wins The Race

Summary Today, we are revisiting Dynavax Technologies Corporation, one of my favorite “rinse, wash, and repeat” covered call trades recently. Dynavax Technologies' Heplisav-B vaccine continues to gain market share, driving solid revenue growth and profitability despite the loss of COVID-19 adjuvant sales. Despite range bound stock performance, Dynavax's profitability and decent liquidity in the options against the equity, make it an attractive investment, with minimal downside risk and potential for solid upside. An updated analysis following second quarter results in August follows in the paragraphs below. Read the full article on Seeking Alpha
Seeking Alpha • Aug 23

Dynavax Technologies: A Two Trick Pony Operating With A Single Trick

Summary Dynavax has experienced fluctuations in stock performance since the author's initial coverage. HEPLISAV-B is Dynavax's primary revenue source for the foreseeable future, with CpG-1018 currently sidelined. Supported by ample liquidity, Dynavax is evaluating business development on a disciplined basis. Read the full article on Seeking Alpha
分析記事 • Aug 14

Some May Be Optimistic About Dynavax Technologies' (NASDAQ:DVAX) Earnings

Dynavax Technologies Corporation's ( NASDAQ:DVAX ) stock was strong despite it releasing a soft earnings report last...
分析記事 • Jul 12

Is Dynavax Technologies (NASDAQ:DVAX) Weighed On By Its Debt Load?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...
分析記事 • May 22

Lacklustre Performance Is Driving Dynavax Technologies Corporation's (NASDAQ:DVAX) Low P/S

With a price-to-sales (or "P/S") ratio of 6.4x Dynavax Technologies Corporation ( NASDAQ:DVAX ) may be sending bullish...
Seeking Alpha • May 10

Dynavax: HEPLISAV-B Growth Up, Pipeline Uncertain

Summary HEPLISAV-B Q1 revenue was $48 million, showing 10% YoY growth. Dynavax's shingles and Tdap vaccines advanced in clinical stages, with data anticipated in the coming quarters. Dynavax's balance sheet remains robust with a significant cash runway. Dynavax remains a "hold," given the challenging prospects beyond the hepatitis B market. Read the full article on Seeking Alpha
Seeking Alpha • Mar 23

Dynavax: Holding Firm Despite Its Missing Cash Cow

Summary Pandemic era CpG 1018 revenues are gone and unlikely to rekindle. HEPLISAV-B revenues create a reliable growing stream of income. Dynavax is fairly valued. Read the full article on Seeking Alpha
分析記事 • Mar 06

Is Dynavax Technologies (NASDAQ:DVAX) A Risky Investment?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
分析記事 • Jan 31

Dynavax Technologies Corporation's (NASDAQ:DVAX) Business And Shares Still Trailing The Industry

Dynavax Technologies Corporation's ( NASDAQ:DVAX ) price-to-sales (or "P/S") ratio of 4.7x might make it look like a...

業績と収益の成長予測

NasdaqGS:DVAX - アナリストの将来予測と過去の財務データ ( )USD Millions
日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数
12/31/2028524138N/AN/A2
12/31/2027451114N/AN/A3
12/31/202639281N/AN/A3
12/31/2025339-48N/AN/A3
9/30/2025331-438191N/A
6/30/2025316-536676N/A
3/31/2025295-605464N/A
12/31/2024277276067N/A
9/30/2024261202327N/A
6/30/2024250173539N/A
3/31/202423695356N/A
12/31/2023232-696101N/A
9/30/202336161118122N/A
6/30/2023459111147152N/A
3/31/2023656236134141N/A
12/31/20227232935663N/A
9/30/2022733320140148N/A
6/30/2022674228142153N/A
3/31/2022470104238247N/A
12/31/202143972326336N/A
9/30/2021258-39192199N/A
6/30/2021163-6101105N/A
3/31/2021113-62-31-27N/A
12/31/202040-75-103-92N/A
9/30/202038-97-112-100N/A
6/30/202035-138-115-94N/A
3/31/202040-129-136-108N/A
12/31/201935-156-151-121N/A
9/30/201930-159-161-132N/A
6/30/201921-163N/A-144N/A
3/31/201914-160N/A-141N/A
12/31/20188-159N/A-131N/A
9/30/20183-146N/A-115N/A
6/30/20181-128N/A-99N/A
3/31/20180-109N/A-82N/A
12/31/20170-95N/A-78N/A
9/30/20178-89N/A-86N/A
6/30/20178-102N/A-97N/A
3/31/201710-111N/A-105N/A
12/31/201611-112N/A-107N/A
9/30/20164-118N/A-103N/A
6/30/20165-113N/A-97N/A
3/31/20164-108N/A-96N/A
12/31/20154-107N/A-93N/A
9/30/20156-102N/A-88N/A
6/30/20157-102N/A-88N/A
3/31/20158-103N/A-87N/A

アナリストによる今後の成長予測

収入対貯蓄率: DVAXは今後 3 年間で収益性が向上すると予測されており、これは 貯蓄率 ( 3.4% ) よりも高い成長率であると考えられます。

収益対市場: DVAX今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。

高成長収益: DVAX今後 3 年以内に収益を上げることが予想されます。

収益対市場: DVAXの収益 ( 12.4% ) US市場 ( 11.6% ) よりも速いペースで成長すると予測されています。

高い収益成長: DVAXの収益 ( 12.4% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: DVAXの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

成長企業の発掘

7D

1Y

7D

1Y

7D

1Y

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/02/10 06:48
終値2026/02/09 00:00
収益2025/09/30
年間収益2024/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Dynavax Technologies Corporation 3 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。10

アナリスト機関
Elemer PirosCantor Fitzgerald & Co.
Douglas BuchananCitizens JMP Securities, LLC
Jason ButlerCitizens JMP Securities, LLC